What one share of Zentalis Pharmaceuticals holds
We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Zentalis Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.96 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.80 |
| Cash and investments | $0.35 |
| Book value | $2.00 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$8.16 | $0.06 | −$7.06 | — | −$13.09 |
| 2020 | — | −$4.19 | $0.03 | −$3.12 | — | $7.52 |
| 2021 | — | −$3.72 | $0.14 | −$3.75 | — | $8.00 |
| 2022 | $0.00 | −$4.48 | $0.05 | −$3.15 | — | $7.32 |
| 2023 | $0.00 | −$4.47 | $0.01 | −$3.19 | — | $6.18 |
| 2024 | $0.95 | −$2.33 | $0.00 | −$2.41 | — | $4.73 |
| 2025 | $0.00 | −$1.91 | $0.00 | −$1.74 | — | $3.13 |
Common questions about Zentalis Pharmaceuticals
How much does one share of Zentalis Pharmaceuticals earn?
Over the last 12 months, Zentalis Pharmaceuticals lost $1.96 for each share.
Does Zentalis Pharmaceuticals pay a dividend?
Zentalis Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Zentalis Pharmaceuticals’s book value per share?
Zentalis Pharmaceuticals’s book value is $2.00 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Zentalis Pharmaceuticals have?
Each share of Zentalis Pharmaceuticals has $0.35 of cash and investments, as of June 30, 2026.
What is Zentalis Pharmaceuticals’s free cash flow per share?
−$1.80 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Zentalis Pharmaceuticals bought back shares?
Zentalis Pharmaceuticals’s share count rose about 1184% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.